The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
Open accessAbstract
OBJECTIVE: To review existing regulations and policies utilised by countries to enable patient access to orphan drugs. METHODS: A review of the literature (1998 to 2014) was performed to identify relevant, peer-reviewed articles. Using content analysis, we synthesised regulations and policies for access to orphan drugs by type and by country. RESULTS: Fifty seven articles and 35 countries were included in this review. Six broad categories of regulation and policy instruments were identified: national orphan drug policies, orphan drug designation, marketing authorization, incentives, marketing exclusivity, and pricing and reimbursement. The availability of orphan drugs depends on individual country's legislation and regulations including national orphan drug policies, orphan drug designation, marketing authorization, marketing exclusivity and incentives such as tax credits to ensure research, development and marketing. The majority of countries (27/35) had in place orphan drug legislation. Access to orphan drugs depends on individual country's pricing and reimbursement policies, which varied widely between countries. High prices and insufficient evidence often limit orphan drugs from meeting the traditional health technology assessment criteria, especially cost-effectiveness, which may influence access. CONCLUSIONS: Overall many countries have implemented a combination of legislations, regulations and policies for orphan drugs in the last two decades. While these may enable the availability and access to orphan drugs, there are critical differences between countries in terms of range and types of legislations, regulations and policies implemented. Importantly, China and India, two of the largest countries by population size, both lack national legislation for orphan medicines and rare diseases, which could have substantial negative impacts on their patient populations with rare diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Danaei, G., Ding, E. L., Mozaffarian, D., Taylor, B., Rehm, J., Murray, C. J. L., & Ezzati, M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000058 · Cited by 2,860
Socio-economic burden of rare diseases: A systematic review of cost of illness evidence
Angelis, A., Tordrup, D., & Kanavos, P. (2015) · Health Policy · doi:10.1016/j.healthpol.2014.12.016 · Cited by 306
Assessing the economic challenges posed by orphan drugs
Drummond, M. F., Wilson, D. A., Kanavos, P., Ubel, P., & Rovira, J. (2007) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462307051550 · Cited by 279
Pricing and reimbursement of orphan drugs: the need for more transparency
Simoens, S. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-42 · Cited by 260
Rare diseases and orphan drugs
Melnikova, I. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3654 · Cited by 213
Rare diseases, orphan drugs and their regulation: questions and misconceptions
Tambuyzer, E. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3275 · Cited by 182
Georges, A., Bonneau, J., Bonnefont-Rousselot, D., Champigneulle, J., Rabès, J. P., Abifadel, M., Aparicio, T., Guenedet, J. C., Bruckert, E., Boileau, C., et al. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-1 · Cited by 175
Kumagi, T., & Heathcote, E. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-1 · Cited by 174
Hughes-Wilson, W., Palma, A., Schuurman, A., & Simoens, S. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-74 · Cited by 170
The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
Wellman-Labadie, O., & Zhou, Y. (2010) · Health Policy · doi:10.1016/j.healthpol.2009.12.001 · Cited by 166
Incentives for orphan drug research and development in the United States
Seoane-Vazquez, E. C., Rodríguez-Monguió, R., Szeinbach, S. L., & Visaria, J. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-33 · Cited by 148
European regulation on orphan medicinal products: 10 years of experience and future perspectives
Westermark, K., Holm, B. B., Söderholm, M., Llinares-Garcia, J., Rivière, F., Aarum, S., Butlen‐Ducuing, F., Tsigkos, S., Wilk-Kachlicka, A., N'Diamoi, C., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3445 · Cited by 145
Orphan drugs: the regulatory environment
Franco, P. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.08.009 · Cited by 144
Orphan drug: Development trends and strategies
Sharma, A., Jacob, A., Tandon, M., & Kumar, D. (2010) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.72128 · Cited by 137
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
Schey, C., Milanova, T. F., & Hutchings, A. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-62 · Cited by 133
Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU
Joppi, R., Bertelè, V., & Garattini, S. K. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1423-2 · Cited by 119
Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives
Song, P. (2012) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2012.v1.1.3 · Cited by 117
What Is Wrong with Orphan Drug Policies?
Côté, A., & Keating, B. (2012) · Value in Health · doi:10.1016/j.jval.2012.09.004 · Cited by 113
Rare essentials drugs for rare diseases as essential medicines
Stolk, P. (2006) · Bulletin of the World Health Organization · doi:10.2471/blt.06.031518 · Cited by 110
Availability of and Access to Orphan Drugs
Blankart, C. R., Stargardt, T., & Schreyögg, J. (2010) · PharmacoEconomics · doi:10.2165/11539190-000000000-00000 · Cited by 87
de la Paz, M. P., & Groft, S. C. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-9485-8 · Cited by 85
Orphan drugs policies: a suitable case for treatment
Drummond, M., & Towse, A. (2014) · The European Journal of Health Economics · doi:10.1007/s10198-014-0560-1 · Cited by 84
Orphan Drugs for Rare Diseases
Simoens, S., Cassiman, D. M., Dooms, M. M., & Picavet, E. (2012) · Drugs · doi:10.2165/11635320-000000000-00000 · Cited by 74
Accelerating access to treatments for rare diseases
Dunoyer, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3493 · Cited by 62
Orphan drug legislation: lessons for neglected tropical diseases
Villa, S., Compagni, A., & Reich, M. R. (2008) · The International Journal of Health Planning and Management · doi:10.1002/hpm.930 · Cited by 61
Shining a light in the black box of orphan drug pricing
Picavet, E., Morel, T., Cassiman, D. M., & Simoens, S. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-9-62 · Cited by 60
Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe
Denis, A., Mergaert, L., Fostier, C., Cleemput, I., & Simoens, S. (2010) · Applied Health Economics and Health Policy · doi:10.2165/11536990-000000000-00000 · Cited by 50
Sustainable rare diseases business and drug access: no time for misconceptions
Rollet, P., Lemoine, A., & Dunoyer, M. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-109 · Cited by 48
Liu, B., He, L., He, G., & He, Y. (2010) · Journal of Public Health Policy · doi:10.1057/jphp.2010.30 · Cited by 38
Governance of conditional reimbursement practices in the Netherlands
Boon, W., Martins, L., & Koopmanschap, M. A. (2014) · Health Policy · doi:10.1016/j.healthpol.2014.10.013 · Cited by 29
Orphan Drugs for Rare Diseases: Grounds for Special Status
Picavet, E., Dooms, M. M., Cassiman, D. M., & Simoens, S. (2012) · Drug Development Research · doi:10.1002/ddr.21005 · Cited by 26
Delayed access to treatments for rare diseases: Who's to blame?
Feltmate, K., Janiszewski, P. M., Gingerich, S., & Cloutier, M. (2015) · Respirology · doi:10.1111/resp.12498 · Cited by 26
Evaluating and improving orphan drug regulations in Europe: A Delphi policy study
Picavet, E., Cassiman, D. M., & Simoens, S. (2012) · Health Policy · doi:10.1016/j.healthpol.2012.08.023 · Cited by 25
An Overview of the Orphan Medicines Market in Turkey
Kockaya, G., Wertheimer, A. I., Kılıç, P., Tanyerı, P., Vural, İ. M., Akbulat, A., Artıran, G., & Kerman, S. (2014) · Value in Health Regional Issues · doi:10.1016/j.vhri.2014.06.009 · Cited by 16
A Regulatory Overview About Rare Diseases
Llinares, J. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-9485-8_12 · Cited by 15
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Brabers, A. E., Moors, E. H. M., van Weely, S., & de Vrueh, R. L. A. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-59 · Cited by 15
Access and availability of orphan drugs in the United States: advances or cruel hoaxes?
Teagarden, J. R., Unger, T. F., & Hirsch, G. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.947265 · Cited by 10
Rare Diseases and Orphan Drugs: A comprehensive approach of strategic perspectives
Hansen, J.-C. (2012) · Journal of Communications In Healthcare · doi:10.1179/1753807612y.0000000001 · Cited by 4
Cited by
Ferreira, C. R. (2019) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61124 · Cited by 498
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Metadata
- Authors
- Gammie, T., Lu, C. Y., & Babar, Z. U.-D.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-10-09
- Volume
- 10
- Issue
- 10
- Pages
- e0140002
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2194206520
- Cited by
- 277
- References
- 40
- FWCI
- 55.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.